Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1019 | 1317 | 1200 | 1484 | 1850 | 4626 |
Fund Return | 1.85% | 31.75% | 20% | 14.07% | 13.09% | 16.55% |
Place in category | - | - | - | - | - | - |
% in Category | 38 | 46 | 36 | 20 | 25 | 26 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
ProFund VP UltraNASDAQ 100 | 250.18M | 2.88 | 9.72 | 27.96 | ||
ProFund VP NASDAQ 100 | 162.7M | 7.03 | 10.37 | 15.97 | ||
ProFunds NASDAQ 100 Fund Investor C | 110.7M | 7.01 | 9.94 | 15.76 | ||
ProFund VP Semiconductor | 102.82M | 8.87 | 24.10 | 24.30 | ||
ProFund VP Technology | 61.14M | 2.57 | 11.77 | 18.37 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Rydex Variable NASDAQ 100 2x Strate | 128.23M | 2.89 | 9.91 | 28.56 | ||
Rydex Variable S P 500 2x Strategy | 39.03M | 2.59 | 13.28 | 18.04 | ||
ProFunds Consumer Services UltraSeI | 32.24M | -7.00 | -3.68 | 11.82 | ||
ProFunds UltraJapan Investor Class | 25.33M | 16.30 | 17.75 | 14.98 | ||
ProFunds Precious Metals UltraSecto | 21.97M | -15.03 | -15.61 | -4.72 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
UnitedHealth | US91324P1021 | 7.76 | 605.87 | -1.43% | |
Djia E-Mini Dow Fut Dec23 | - | 6.99 | - | - | |
Soc 5.19% 11/1/2023 | - | 6.45 | - | - | |
Microsoft | US5949181045 | 4.90 | 425.20 | +0.51% | |
Goldman Sachs | US38141G1040 | 4.40 | 594.22 | +0.28% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Strong Buy | Buy | Buy |
Technical Indicators | Strong Buy | Strong Buy | Strong Buy |
Summary | Strong Buy | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review